Publicacións en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (10)

2023

  1. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

    Frontiers in Immunology, Vol. 14

2022

  1. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  2. In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

    Molecular Therapy - Methods and Clinical Development, Vol. 25, pp. 137-146

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1

2016

  1. GluN3A promotes NMDA spiking by enhancing synaptic transmission in Huntington's disease models

    Neurobiology of Disease, Vol. 93, pp. 47-56

2013

  1. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models

    Nature Medicine, Vol. 19, Núm. 8, pp. 1030-1038

2012

  1. The NMDA receptor subunit GluN3A protects against 3-nitroproprionic-induced striatal lesions via inhibition of calpain activation

    Neurobiology of Disease, Vol. 48, Núm. 3, pp. 290-298

2011

  1. A new kinetic framework for synaptic vesicle trafficking tested in synapsin knock-outs

    Journal of Neuroscience, Vol. 31, Núm. 32, pp. 11563-11577

2009

  1. Downregulation of NR3A-Containing NMDARs Is Required for Synapse Maturation and Memory Consolidation

    Neuron, Vol. 63, Núm. 3, pp. 342-356

2007

  1. Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs

    Biochemical and Biophysical Research Communications, Vol. 353, Núm. 3, pp. 750-755